Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma

Melissa A. Wilson, MD, PhD
Published: Thursday, Jul 27, 2017



Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

These 5-year overall survival data demonstrate that patients are staying on these treatments much longer than we initially anticipated, Wilson explains. Since the median progression-free survival was 11.4 months, to have 5-year data is important to show that there are patients who are still on these targeted therapies. Investigators' concerns were that patients would develop resistance, so it is showing that a select population still has continued benefit using these.

Brain metastases remains to be an unmet need still in the field of melanoma, as clinicians are seeing a number of patients actually recur with brain metastases.
SELECTED
LANGUAGE


Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

These 5-year overall survival data demonstrate that patients are staying on these treatments much longer than we initially anticipated, Wilson explains. Since the median progression-free survival was 11.4 months, to have 5-year data is important to show that there are patients who are still on these targeted therapies. Investigators' concerns were that patients would develop resistance, so it is showing that a select population still has continued benefit using these.

Brain metastases remains to be an unmet need still in the field of melanoma, as clinicians are seeing a number of patients actually recur with brain metastases.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x